American Shared Hospital Services(US:AMS)2026-03-31 21:12Revenue Performance - The Company reported Gamma Knife revenue of $9,185,000 for the year ended December 31, 2025, representing 32.7% of total revenue, down from $9,716,000 and 34.3% in 2024[41]. - Total revenue for the year ended December 31, 2025, was $28,082,000, a decrease of 0.9% compared to $28,340,000 in 2024[212]. - Revenue from the leasing segment decreased by $3,076,000 in 2025 due to a decrease in PBRT volumes and the expiration of three Gamma Knife contracts[212]. - Direct patient service segment revenue increased by $2,973,000 in 2025, driven by the single-unit facility in Puebla, Mexico, and three recently acquired facilities in Rhode Island[212]. - Revenue from LINAC business for 2025 was $11,528,000, representing a 35.4% increase from $8,517,000 in 2024, with the number of LINAC sessions rising to 28,147[213]. - PBRT revenue for 2025 was $7,369,000, a decrease of 26.0% from $9,952,000 in 2024, with the number of PBRT fractions performed dropping to 4,056[214]. - Revenue sharing arrangements accounted for approximately 36% of total revenue in 2025, down from 47% in 2024[197]. - The Company recognized direct patient service revenues of approximately $15,529,000 in 2025, up from $12,556,000 in 2024[200]. Acquisitions and Expansions - The Company acquired a 60% interest in the RI Companies for $2,850,000, which operate three radiation therapy cancer centers in Rhode Island, enhancing its direct patient service business model[24]. - The Company began treating patients at its stand-alone radiation therapy facility in Puebla, Mexico, in July 2024, following the acquisition of the RI Companies[31]. - The Company signed a Joint Venture Agreement to establish Instituto Gamma Knife San Javier Mexico S.A.P.I. de C.V. in Guadalajara, Mexico, with a 70% ownership interest, expected to begin treating patients in mid to late 2026[26]. - The Company completed the RI Acquisition on May 7, 2024, acquiring 60% of the equity interests of the RI Companies, which operate three radiation therapy facilities[169]. Financial Obligations and Compliance - The Company entered into a five-year $22,000,000 credit agreement with Fifth Third Bank, which includes a $9,500,000 term loan and a $7,000,000 revolving line of credit[50]. - As of September 30, 2025, the Company was not in compliance with the minimum unrestricted domestic cash requirement of $5,000,000[55]. - The Company received a limited waiver from Fifth Third regarding its failure to comply with the maximum funded debt-to-EBITDA ratio covenant as of June 30, 2025[54]. - The Company faces substantial doubt about its ability to continue as a going concern due to potential defaults under its credit agreements[64]. - As of December 31, 2025, the Company was not in compliance with the minimum fixed-charge coverage ratio, the maximum funded debt-to-EBITDA ratio, and the Minimum Cash Covenant required by the Credit Agreement[115]. - The Company received notice from Fifth Third on December 10, 2025, asserting that an event of default had occurred under the Credit Agreement due to the failure to satisfy the Minimum Cash Covenant for the fiscal quarter ended September 30, 2025[114]. - The Company is currently in discussions with Fifth Third regarding a waiver and an amendment to the Credit Agreement, but there are no assurances regarding the outcome of such discussions[116]. Operational Challenges - The Company reported a decrease in Gamma Knife leasing volume by 19.2% from 624 procedures in 2024 to 504 in 2025, and a decrease in PBRT procedures by 21.1% from 5,139 to 4,056[186]. - The number of Gamma Knife procedures performed in 2025 decreased by 147, totaling 937 procedures, a decline of 13.6% compared to 1,084 in 2024[216]. - The decline in direct patient service volumes was attributed to downtime for upgrading the Gamma Knife in Peru[216]. - The Company has historically relied on Gamma Knife unit placement and PBRT systems for revenue, but plans to diversify its product mix to include other types of stereotactic radiosurgery equipment[123]. Market and Competitive Landscape - The Company operates a proton therapy system at Orlando Health, competing primarily with conventional LINAC-based radiation therapy, which remains the most common treatment method[68]. - There are currently fewer than 50 proton beam radiation therapy centers in the United States, with no direct competitors in the immediate Orlando area[68]. - The Company faces competition from alternative radiosurgery devices and conventional neurosurgery, which may impact its ability to secure future Gamma Knife procedures and profitability[138]. - The competitive market for the Company's services includes other companies providing alternative financing for Gamma Knife units, which may impact sales[137]. Regulatory and Compliance Issues - The Company believes it is in compliance with federal anti-kickback statutes and other regulations affecting its operations[84]. - The Company faces potential adverse effects from changes in government health care funding policies, which could impact reimbursement rates and service coverage[81]. - The Company has expanded its accounting staff to address material weaknesses in internal controls over financial reporting, but there is no assurance of successful remediation[130]. - The Company believes it is in substantial compliance with the various rules and regulations affecting its businesses[94]. Cybersecurity and Risk Management - Cybersecurity risks are a significant concern, with the Company implementing various policies to safeguard its IT infrastructure and data[157]. - The Company's IT Manager is responsible for managing cybersecurity risks and ensuring compliance with security policies and regulations[162]. - The Company has identified cybersecurity risks and is committed to investing in and strengthening its cybersecurity infrastructure[166]. Employee and Governance Information - The Company had a workforce of 44 full-time employees in the United States and 38 full-time employees across its facilities in Peru, Ecuador, and Mexico as of December 31, 2025[97]. - Officers and directors collectively own approximately 23.8% of the Company's outstanding common stock, which may influence corporate governance and strategic decisions[152]. - The Company does not anticipate paying dividends in the foreseeable future, relying on market price appreciation for shareholder returns[155].